Read more about the article Entera Bio developed a delivery platform for replacing injections with pills; the Company has two drugs in clinical phases; market potential for their platform is significant; Entera Bio recently entered into a $270 million license agreement with Amgen; price target is set at $17.6

Entera Bio developed a delivery platform for replacing injections with pills; the Company has two drugs in clinical phases; market potential for their platform is significant; Entera Bio recently entered into a $270 million license agreement with Amgen; price target is set at $17.6

Continue ReadingEntera Bio developed a delivery platform for replacing injections with pills; the Company has two drugs in clinical phases; market potential for their platform is significant; Entera Bio recently entered into a $270 million license agreement with Amgen; price target is set at $17.6
Read more about the article SAFE-T. NASDAQ IPO – $7.3M raised strengthens equity structure; significant growth in revenues and backlog offset by a substantially increased burn rate due to operational and technological expansion; valuation retained, however due to additional shares, target price decreased to NIS 3.85.

SAFE-T. NASDAQ IPO – $7.3M raised strengthens equity structure; significant growth in revenues and backlog offset by a substantially increased burn rate due to operational and technological expansion; valuation retained, however due to additional shares, target price decreased to NIS 3.85.

Continue ReadingSAFE-T. NASDAQ IPO – $7.3M raised strengthens equity structure; significant growth in revenues and backlog offset by a substantially increased burn rate due to operational and technological expansion; valuation retained, however due to additional shares, target price decreased to NIS 3.85.
Read more about the article Safe-T: The company continues to successfully implement its growth strategy. Raised capital, launched a new web site and marketing activities, received first orders for its newly announced solution and is gearing up for dual-trading. Price target remains at NIS 9.38.

Safe-T: The company continues to successfully implement its growth strategy. Raised capital, launched a new web site and marketing activities, received first orders for its newly announced solution and is gearing up for dual-trading. Price target remains at NIS 9.38.

Continue ReadingSafe-T: The company continues to successfully implement its growth strategy. Raised capital, launched a new web site and marketing activities, received first orders for its newly announced solution and is gearing up for dual-trading. Price target remains at NIS 9.38.